Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis
Overall Grade: F (Concerning)
View interactive company profile →
Harmony Biosciences Holdings, Inc. faces challenges in financial performance that warrant careful analysis.
Key Metrics:
| Metric | Value | Context |
|---|---|---|
| ROIC | 16.3% | Solid returns |
| FCF Margin | 40.1% | Strong cash generation |
| Debt/Equity | 0.2x | Conservative leverage |
Investment Thesis: Strong return on invested capital of 16.3% suggests durable competitive advantages and efficient capital allocation.
What is Harmony Biosciences Holdings, Inc.'s Profitability and ROIC?
Harmony Biosciences Holdings, Inc. generates strong returns on invested capital at 16.3%, indicating efficient capital allocation and competitive advantages. Gross margin of 77.2% with operating margin at 24.0% reflects the company's strong market position.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 16.3% | Good | Strong capital efficiency |
| Return on Equity (ROE) | 20.5% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 77.2% | Excellent | Strong pricing power |
| Operating Margin | 24.0% | Excellent | Efficient operations |
How Strong is Harmony Biosciences Holdings, Inc.'s Cash Flow Quality?
Harmony Biosciences Holdings, Inc. generated $347.9M in free cash flow over the trailing twelve months, representing a 40.1% margin. Cash earnings quality is strong, with operating cash flow exceeding net income by 2.2x.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Free Cash Flow Margin | 40.1% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $347.9M | Good | Positive cash generation |
| OCF/Net Income | 2.2x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
What is Harmony Biosciences Holdings, Inc.'s Financial Health?
Harmony Biosciences Holdings, Inc. maintains a net cash position of $611.9M, providing significant financial flexibility.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| Debt to Equity | 0.2x | Excellent | Conservative capital structure |
| Net Cash Position | $611.9M | Excellent | Net cash positive |
Is Harmony Biosciences Holdings, Inc. Stock Overvalued or Undervalued?
Harmony Biosciences Holdings, Inc. trades at a P/E of 13.6x, representing a premium to the sector median of N/A. Free cash flow yield of 16.2% offers attractive cash returns.
Key Metrics
| Metric | Value | Rating | Interpretation |
|---|---|---|---|
| P/E Ratio | 13.6x | Adequate | Reasonable valuation |
| EV/Sales | 2.0x | Excellent | Attractive revenue multiple |
| FCF Yield | 16.2% | Excellent | Attractive cash return |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 16.3% | Top 25% | - |
| Free Cash Flow Margin | 40.1% | Top 5% | - |
| Gross Margin | 77.2% | Top 50% | 1.3x above |
| Operating Margin | 24.0% | Top 25% | 5.3x above |
| Return on Equity (ROE) | 20.5% | Top 25% | - |
| P/E Ratio | 13.6x | N/A | - |
Rating Thresholds
Return on Invested Capital (ROIC)
Measures how efficiently a company uses its debt and equity capital to generate profits. ROIC above 15% typically indicates a competitive moat.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Exceptional capital efficiency, strong competitive moat |
| Good | 12% - 20% | Above-average returns, sustainable competitive position |
| Adequate | 8% - 12% | Around cost of capital, moderate competitive position |
| Warning | 4% - 8% | Below cost of capital, value may be eroding |
| Red flag | < 4% | Significant capital destruction, fundamental issues |
Current: 16.3% (Good - Top 25% of sector (median: 0.0%))
Free Cash Flow Margin
The percentage of revenue converted to free cash flow. Higher margins indicate stronger cash generation and business quality.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 20% | Strong cash generation, high-quality business |
| Good | 10% - 20% | Healthy cash conversion |
| Adequate | 5% - 10% | Moderate cash generation |
| Warning | 0% - 5% | Thin cash margins, capital intensive |
| Red flag | < 0% | Cash burn, potential liquidity concerns |
Current: 40.1% (Excellent - Top 5% of sector (median: 0.0%))
Gross Margin
Revenue minus cost of goods sold as a percentage. Higher gross margins indicate pricing power and competitive advantage.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 50% | Strong pricing power and competitive moat |
| Good | 30% - 50% | Healthy margins, differentiated product |
| Adequate | 20% - 30% | Moderate margins, competitive industry |
| Warning | 10% - 20% | Thin margins, commodity-like business |
| Red flag | < 10% | Very thin margins, structural challenges |
Current: 77.2% (Excellent - Top 50% of sector (median: 61.4%))
Debt to Equity Ratio
Total debt divided by shareholders' equity. Lower ratios indicate more conservative financing and reduced financial risk.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | < 0.3x | Conservative leverage, strong balance sheet |
| Good | 0.3x - 0.7x | Moderate leverage, healthy financial position |
| Adequate | 0.7x - 1.5x | Elevated leverage, monitor closely |
| Warning | 1.5x - 3.0x | High leverage, increased financial risk |
| Red flag | > 3.0x | Excessive leverage, potential distress risk |
Current: 18.8% (Excellent)
P/E Ratio (Price-to-Earnings)
Stock price divided by earnings per share. Lower P/E may indicate undervaluation, while higher P/E suggests growth expectations.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | < 15x | Attractively valued, potential opportunity |
| Good | 15x - 25x | Fair value for quality company |
| Adequate | 25x - 35x | Growth premium, justify with earnings growth |
| Warning | 35x - 50x | High expectations priced in |
| Red flag | > 50x or negative | Speculative valuation or losses |
Current: 13.6x (Adequate)
Free Cash Flow Yield
Free cash flow per share divided by stock price. Higher FCF yield indicates better cash return relative to valuation.
| Rating | Range | Interpretation |
|---|---|---|
| Excellent | > 8% | High cash return, potential value opportunity |
| Good | 5% - 8% | Solid cash yield |
| Adequate | 3% - 5% | Moderate cash return |
| Warning | 1% - 3% | Low cash yield, growth expectations |
| Red flag | < 1% | Minimal cash return to shareholders |
Current: 16.2% (Excellent)
Frequently Asked Questions
Q: What is Harmony Biosciences Holdings, Inc.'s Return on Invested Capital (ROIC)?
Harmony Biosciences Holdings, Inc. (HRMY) has a trailing twelve-month Return on Invested Capital (ROIC) of 16.3%. This compares above the sector median of 0.0%. An ROIC between 12-20% indicates solid capital allocation and sustainable competitive position.
Q: What is Harmony Biosciences Holdings, Inc.'s Free Cash Flow Margin?
Harmony Biosciences Holdings, Inc. (HRMY) has a free cash flow margin of 40.1%, generating $347.9 million in free cash flow over the trailing twelve months. A FCF margin above 20% indicates excellent cash conversion and a high-quality business model.
Q: Is Harmony Biosciences Holdings, Inc. stock overvalued or undervalued?
Harmony Biosciences Holdings, Inc. (HRMY) trades at a P/E ratio of 13.6x, which is above the sector median of N/A. The EV/Sales multiple is 2.0x. Free cash flow yield is 16.2%, which represents an attractive cash return to investors.
Q: What is Harmony Biosciences Holdings, Inc.'s revenue and earnings growth?
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 21.5% year-over-year. Earnings per share increased by 8.4% compared to the prior year. Double-digit revenue growth indicates strong demand and market share gains.
Q: How does Harmony Biosciences Holdings, Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, Harmony Biosciences Holdings, Inc. (HRMY) shows: ROIC of 16.3% is above the sector median of 0.0% (Top 22%). FCF margin of 40.1% exceeds the sector median of 0.0% (Top 0% of sector). Gross margin at 77.2% is 15.8 percentage points higher than sector peers. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Harmony Biosciences Holdings, Inc.?
Investors in Harmony Biosciences Holdings, Inc. (HRMY) should monitor these potential warning signs: 1) ROIC has been declining, potentially signaling deteriorating competitive position. Regular monitoring of SEC filings and quarterly trends is recommended.
Data Source: Data sourced from 10-Q filed 2025-11-04. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
This analysis is for informational purposes only and does not constitute investment advice.